Shots:

• The approval is based on P-IIIb LIBERTY (NCT03096834) study results assessing Aimovig (140mg) vs PBO for duration of 12 weeks
• The study resulted in 50% reduction of monthly migraine days sustained up to 15 months with the use of acute migraine drugs
• Aimovig (erenumab-aooe) is a novel drug used for targeting Calcitonin Gene-Related Peptide Receptor (CGRP-R)- with its awaited EMA approval

Ref: Amgen | Image: Axios